Reponse to ALKS/NKTR
Our first post! Time for a whisky -- well, it is almost always time for a whisky.
Yes, I still like ALKS and NKTR -- Alkermes had very strong earnings in Q4, announced after the close today, and raised guidance for 2007. And Vivitrol, the alcoholism treatment that disappointed last year, had smallish ($5MM) but better than expected sales.
Nektar seems to have a solid technical floor at $12 -- I am a bull on this stock despite its steady decline.
Michael
Comments (2)
i am interested in gnvc which is appearing at the conference if you can please comment on their future
I will visit with them, thanks for the input.
MS
Posted by messmore Kendall | February 8, 2007 6:10 PM
Posted on February 8, 2007 18:10
Michael, thanks for the blog. The more real-time, personal contact will be very helpful to me with trading bio-tech stocks.
Posted by Michael | February 9, 2007 12:51 AM
Posted on February 9, 2007 00:51